PARP14 is an ADP-ribosyltransferase that transfers ADP-ribose from NAD+ onto the appropriate protein target. PARP14 selectively binds to STAT6 and promotes expression of IL-4-regulated genes, thus modulating inflammatory signaling pathways. PARP14 is overexpressed in tissues from patients with dermatomyositis, atopic dermatitis, psoriasis and other inflammatory disorder cells compared to normal tissues.
TRPV3 is a temperature-sensitive transient receptor potential (TRP) ion channel that functions as a regulator of skin homeostasis. The epidermal overexpression of TRPV3 is linked to dermatological conditions with increased inflammation signals such as dermatitis, hyperkeratosis, keratoderma or pruritus.
Gossamer Bio Inc. has divulged trisubstituted pyridines acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of asthma, atopic dermatitis, contact dermatitis, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis and allergic rhinitis, among others.
A heart-protective cardiac myosin inhibitor and two biologics – one for a type of non-Hodgkin lymphoma and another for an inflammatory skin condition – were among the therapies recommended for approval by the EMA’s Committee for Medicinal Products for Human Use this week.
To date, only one drug has been approved for the treatment of itch (persistent pruritus) and it only targets a small portion of the patient population. Researchers from Mallinckrodt plc have unveiled gastrin-releasing peptide receptor (GRPR) as an itch-specific receptor for nonhistaminergic itch.
Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic dermatitis, actinic keratosis and psoriasis.
RHOJ, a small GTPase, could hold the key to the survival of tumor cells during cancer treatments. When epithelial cells transformed into mesenchymal cells, the Rho-related GTP-binding protein RhoJ regulated their resistance to chemotherapy. The scientists observed this mechanism in mouse models of skin squamous cell carcinoma, but their results could go beyond just one type of cancer. When the team started its experiments, which were published March 23, 2023, in Nature, “I had never heard about RHOJ before,” the lead author Cédric Blanpain told BioWorld. Blanpain is the director of the Laboratory of Stem Cells and Cancer at the Université Libre de Bruxelles (ULB).
RSS
